Table 1.
Univariate analysis of prognostic factors in patients with thyroid cancer in Yantai during 2012 − 2022
| Characteristics | Death cases (%) |
OS (%, 95%CI) | HR (95%CI) | p-value | ||
|---|---|---|---|---|---|---|
| 3-year | 5-year | |||||
| Diagnosis period | 2012 − 2016 | 201(10.26) | 93.98(92.93 − 95.04) | 91.78(90.57 − 93.00) | 1.000 (reference) | |
| 2017 − 2022 | 178(2.00) | 98.19(97.91 − 98.48) | 97.55(97.17 − 97.93) | 0.282(0.229 − 0.349) | < 0.001 | |
| Gender | Male | 141(5.49) | 95.52(94.69 − 96.36) | 93.93(92.89 − 94.98) | 1.000 (reference) | |
| Female | 238(2.87) | 97.94(97.62 − 98.25) | 96.91(96.47 − 97.34) | 0.516(0.419 − 0.635) | < 0.001 | |
| Age group (years) | < 45 | 35(0.84) | 99.39(99.14 − 99.64) | 98.95(98.58 − 99.32) | 1.000 (reference) | |
| 45 − 64 | 143(2.51) | 98.32(97.97 − 98.67) | 97.25(96.75 − 97.75) | 2.948(2.037 − 4.267) | < 0.001 | |
| ≥ 65 | 201(19.92) | 83.78(81.47 − 86.15) | 79.51(76.79 − 82.33) | 25.657(17.918 − 36.739) | < 0.001 | |
| Place of residence | Urban | 164(2.33) | 98.26(97.95 − 98.58) | 97.48(97.06 − 97.90) | 1.000 (reference) | |
| Rural | 215(5.62) | 95.72(95.05 − 96.39) | 93.83(92.95 − 94.72) | 2.475(2.020 − 3.033) | < 0.001 | |
| Occupational class | Service class | 10(2.30) | 98.52(97.35 − 99.71) | 98.20(96.88 − 99.54) | 1.000 (reference) | |
| White-collar class | 15(3.16) | 97.61(96.22 − 99.02) | 96.94(95.28 − 98.63) | 1.337(0.601 − 2.976) | 0.477 | |
| Blue‐collar class | 260(4.24) | 96.83(96.38 − 97.28) | 95.57(95.00 − 96.14) | 1.886(1.003 − 3.547) | 0.049 | |
| others | 94(2.46) | 98.13(97.68 − 98.58) | 96.95(96.26 − 97.65) | 1.217(0.634 − 2.336) | 0.555 | |
| Site | Unilateral | 291(3.41) | 97.56(97.23 − 97.91) | 96.25(95.78 − 96.72) | 1.000 (reference) | |
| Isthmus | 42(25.00) | 73.60(66.90 − 80.97) | 73.60(66.90 − 80.97) | 11.425(8.240 − 15.841) | < 0.001 | |
| Multiple | 46(2.13) | 98.38(97.81 − 98.95) | 97.75(97.04 − 98.47) | 0.622(0.456 − 0.849) | 0.003 | |
| Size (cm) | ≤ 3 | 189(1.89) | 98.67(98.44 − 98.91) | 97.57(97.21 − 97.92) | 1.000 (reference) | |
| > 3 | 190(22.41) | 50.17(44.71 − 56.31) | 48.08(42.63 − 54.22) | 3.214(2.615 − 3.949) | < 0.001 | |
| Lymph node metastasis | No | 75(1.05) | 99.63(99.49 − 99.77) | 98.62(98.31 − 98.94) | 1.000 (reference) | |
| Yes | 304(8.15) | 89.69(88.41 − 90.98) | 87.54(85.99 − 89.13) | 5.110(2.802 − 13.830) | < 0.001 | |
| TgAb (IU/ml) | < 115 | 37(0.57) | 99.63(99.48 − 99.79) | 98.71(98.32 − 99.10) | 1.000 (reference) | |
| 115 − 500 | 75(14.73) | 88.76(86.06 − 91.55) | 88.76(86.06 − 91.55) | 1.143(1.105 − 1.611) | < 0.001 | |
| > 500 | 267(31.49) | 38.39(32.60 − 45.20) | 16.67(12.30 − 22.59) | 12.872(9.822 − 16.870) | < 0.001 | |
| Pathological type | PTC | 324(3.04) | 97.73(97.43 − 98.02) | 96.68(96.29 − 97.08) | 1.000 (reference) | |
| FTC | 14(12.07) | 91.75(86.70 − 97.09) | 89.22(83.28 − 95.57) | 3.615(2.116 − 6.176) | < 0.001 | |
| MTC | 19(27.94) | 85.18(76.67 − 94.64) | 69.78(58.11 − 83.79) | 9.971(6.274 − 15.848) | < 0.001 | |
| ATC* | 22(84.62) | 46.15(30.47 − 69.91) | 23.08(10.94 − 48.66) | 71.125(45.668 − 110.770) | < 0.001 | |
| AJCC stage | I | 13(0.15) | 99.88(99.80 − 99.96) | 99.81(99.69 − 99.92) | 1.000 (reference) | |
| II | 80(6.91) | 97.18(96.20 − 98.16) | 92.98(91.24 − 94.75) | 4.041(2.248 − 7.266) | < 0.001 | |
| III | 256(21.53) | 82.25(80.03 − 84.52) | 78.28(75.85 − 80.79) | 13.094(7.495 − 22.878) | < 0.001 | |
| IV | 30(50.85) | 54.38(42.81 − 69.08) | 54.38(42.81 − 69.08) | 39.519(20.607 − 75.790) | < 0.001 | |
| Treatment timing (months) | ≤ 3 | 75(2.11) | 98.66(98.41 − 98.81) | 97.71(97.35 − 98.08) | 1.000 (reference) | |
| > 3 | 114(9.60) | 89.90(88.38 − 91.43) | 87.55(85.80 − 89.33) | 5.287(4.316 − 6.476) | < 0.001 | |
| Therapeutic approach | Surgery | 304(2.89) | 97.36(97.05 − 97.68) | 96.20(95.78 − 96.61) | 1.000 (reference) | |
| Surgery + RI | 6(1.77) | 98.35(95.52 − 100) | 98.35(96.52 − 100) | 0.951(0.304 − 2.971) | 0.931 | |
| All patients | 379(3.49) | 97.36(97.05 − 97.68) | 96.20(95.79 − 96.61) | ― | ― | |
TgAb Anti-thyroglobulin antibodies, PTC Papillary thyroid cancer, FTC Follicular thyroid cancer, MTC Medullary thyroid cancer, ATC Anaplastic thyroid cancer, RI Radioiodine
*The longest survival among patients with ATC in this study was 1.98 years, which is less than 2 years, so survival rates at 6 months and 1 year were calculated